## Angelo Sala

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2055047/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Estrogen Prevents the Lipopolysaccharide-Induced Inflammatory Response in Microglia. Journal of Neuroscience, 2001, 21, 1809-1818.	1.7	415
2	Inhaled PGE2 prevents aspirin-induced bronchoconstriction and urinary LTE4 excretion in aspirin-sensitive asthma American Journal of Respiratory and Critical Care Medicine, 1996, 153, 572-575.	2.5	252
3	Olive Phenol Hydroxytyrosol Prevents Passive Smoking–Induced Oxidative Stress. Circulation, 2000, 102, 2169-2171.	1.6	168
4	Olive Oils Rich in Natural Catecholic Phenols Decrease Isoprostane Excretion in Humans. Biochemical and Biophysical Research Communications, 2000, 278, 797-799.	1.0	152
5	Cysteinyl-leukotrienes and their receptors in asthma and other inflammatory diseases: Critical update and emerging trends. Medicinal Research Reviews, 2007, 27, 469-527.	5.0	150
6	Muscarinic receptors, leukotriene B4 production and neutrophilic inflammation in COPD patients. Allergy: European Journal of Allergy and Clinical Immunology, 2005, 60, 1361-1369.	2.7	133
7	Behavior and Clinical Relevance of Histamine and Leukotrienes C <sub>4</sub> and B <sub>4</sub> in Grass Pollen-Induced Rhinitis. The American Review of Respiratory Disease, 1987, 136, 357-362.	2.9	120
8	The Atlas of Inflammation Resolution (AIR). Molecular Aspects of Medicine, 2020, 74, 100894.	2.7	110
9	Increased prostaglandin E2 concentrations and cyclooxygenase-2 expression in asthmatic subjects with sputum eosinophilia. Journal of Allergy and Clinical Immunology, 2003, 112, 709-716.	1.5	107
10	Transcellular biosynthesis of eicosanoids. Pharmacological Reports, 2010, 62, 503-510.	1.5	97
11	Release of Leukotriene A4 Leukotriene B4 from Human Polymorphonuclear Leukocytes. Journal of Biological Chemistry, 1996, 271, 17944-17948.	1.6	89
12	IL-33/ST2 axis controls Th2/IL-31 and Th17 immune response in allergic airway diseases. Immunobiology, 2015, 220, 954-963.	0.8	81
13	Chronic obstructive pulmonary disease and neutrophil infiltration: role of cigarette smoke and cyclooxygenase products. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2010, 298, L261-L269.	1.3	79
14	Transcellular biosynthesis of cysteinyl leukotrienes in vivo during mouse peritoneal inflammation. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 8296-8301.	3.3	78
15	Pharmacological modulation of the leukotriene pathway in allergic airway disease. Drug Discovery Today, 2007, 12, 404-412.	3.2	76
16	Mediator release after endobronchial antigen challenge in patients with respiratory allergy. Journal of Allergy and Clinical Immunology, 1990, 85, 906-913.	1.5	73
17	Transcellular biosynthesis of eicosanoid lipid mediators. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2015, 1851, 377-382.	1.2	71
18	The Cycloxygenase-2 inhibitor SC58236 is neuroprotective in an in vivo model of focal ischemia in the rat. Neuroscience Letters, 2001, 303, 91-94.	1.0	69

Angelo Sala

#	Article	IF	CITATIONS
19	CHF6001 I: A Novel Highly Potent and Selective Phosphodiesterase 4 Inhibitor with Robust Anti-Inflammatory Activity and Suitable for Topical Pulmonary Administration. Journal of Pharmacology and Experimental Therapeutics, 2015, 352, 559-567.	1.3	67
20	15(S)-HETE modulates LTB <sub>4</sub> production and neutrophil chemotaxis in chronic bronchitis. American Journal of Physiology - Cell Physiology, 2000, 279, C1249-C1258.	2.1	66
21	Cysteinylâ€leukotriene receptor activation in brain inflammatory reactions and cerebral edema formation: a role for transcellular biosynthesis of cysteinyl leukotrienes. FASEB Journal, 2004, 18, 842-844.	0.2	66
22	Inhibition by lipoxygenase products of TXA2-like responses of platelets and vascular smooth muscle. Biochemical Pharmacology, 1988, 37, 1275-1280.	2.0	62
23	Estrogen Receptor-α as a Drug Target Candidate for Preventing Lung Inflammation. Endocrinology, 2010, 151, 174-184.	1.4	61
24	INHIBITION OF LEUKOCYTE LEUKOTRIENE B4 PRODUCTION BY AN OLIVE OIL-DERIVED PHENOL IDENTIFIED BY MASS-SPECTROMETRY. Thrombosis Research, 1997, 87, 315-322.	0.8	58
25	Neutrophils, Endothelial Cells, and Cysteinyl Leukotrienes: A New Approach to Neutrophil-Dependent Inflammation?. Biochemical and Biophysical Research Communications, 2001, 283, 1003-1006.	1.0	58
26	Isoprostanes and Oxidative Stress in Off-Pump and On-Pump Coronary Bypass Surgery. Annals of Thoracic Surgery, 2006, 81, 562-567.	0.7	58
27	Evidence of PAF-acether Metabolic Pathway Activation in Antigen Challenge of Upper Respiratory Airways. The American Review of Respiratory Disease, 1989, 140, 142-147.	2.9	56
28	Formation of sulphidopeptideâ€leukotrienes by cellâ€cell interaction causes coronary vasoconstriction in isolated, cellâ€perfused heart of rabbit. British Journal of Pharmacology, 1993, 110, 1206-1212.	2.7	56
29	Lipid Peroxidation and 5-Lipoxygenase Activity in Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2005, 171, 838-843.	2.5	55
30	Differential Metabolism of Exogenous and Endogenous Arachidonic Acid in Human Neutrophils. Journal of Biological Chemistry, 1999, 274, 28264-28269.	1.6	49
31	Leukotrienes in Cardiovascular Diseases. American Journal of Respiratory and Critical Care Medicine, 2000, 161, S112-S116.	2.5	49
32	15-Lipoxygenase expression and 15(S)-hydroxyeicoisatetraenoic acid release and reincorporation in	1.5	48
33	Exhaled and non-exhaled non-invasive markers for assessment of respiratory inflammation in patients with stable COPD and healthy smokers. Journal of Breath Research, 2016, 10, 017102.	1.5	48
34	Cyclooxygenase-2 and synthesis of PGE2 in human bronchial smooth-muscle cells American Journal of Respiratory and Critical Care Medicine, 1997, 155, 864-868.	2.5	47
35	Effect of Endogenous and Exogenous Prostaglandin E2on Interleukin-1 β –Induced Cyclooxygenase-2 Expression in Human Airway Smooth-Muscle Cells. American Journal of Respiratory and Critical Care Medicine, 2000, 162, 2272-2277.	2.5	47
36	Activation of the orphan nuclear receptor RORα counteracts the proliferative effect of fatty acids on prostate cancer cells: Crucial role of 5-lipoxygenase. International Journal of Cancer, 2004, 112, 87-93.	2.3	45

#	Article	IF	CITATIONS
37	Two-pronged approach to anti-inflammatory therapy through the modulation of the arachidonic acid cascade. Biochemical Pharmacology, 2018, 158, 161-173.	2.0	41
38	Interleukin-4 Enhances 15-Lipoxygenase Activity and Incorporation of 15(S)-HETE into Cellular Phospholipids in Cultured Pulmonary Epithelial Cells. American Journal of Respiratory Cell and Molecular Biology, 1999, 20, 61-68.	1.4	40
39	Dual COXIB/TP antagonists: a possible new twist in NSAID pharmacology and cardiovascular risk. Trends in Pharmacological Sciences, 2010, 31, 102-107.	4.0	40
40	Azithromycin inhibits nuclear factorâ€ <i>Ĵº</i> B activation during lung inflammation: an in vivo imaging study. Pharmacology Research and Perspectives, 2014, 2, e00058.	1.1	40
41	CHF6001 II: A Novel Phosphodiesterase 4 Inhibitor, Suitable for Topical Pulmonary Administration—In Vivo Preclinical Pharmacology Profile Defines a Potent Anti-Inflammatory Compound with a Wide Therapeutic Window. Journal of Pharmacology and Experimental Therapeutics, 2015, 352, 568-578.	1.3	40
42	From Field to Health:Â A Simple Way To Increase the Nutraceutical Content of Grape As Shown by NO-Dependent Vascular Relaxation. Journal of Agricultural and Food Chemistry, 2006, 54, 5344-5349.	2.4	37
43	Bioactive Compounds in Edible Oils and Their Role in Oxidative Stress and Inflammation. Frontiers in Physiology, 2021, 12, 659551.	1.3	37
44	Effects of loratadine on cytosolic Ca2+ levels and leukotriene release: novel mechanisms of action independent of the anti-histamine activity. European Journal of Pharmacology, 1994, 266, 219-227.	2.7	35
45	eNOS, COX-2, and prostacyclin production are impaired in endothelial cells from diabetics. Biochemical and Biophysical Research Communications, 2006, 339, 188-190.	1.0	33
46	Tramadol anti-inflammatory activity is not related to a direct inhibitory action on prostaglandin endoperoxide synthases. European Journal of Pain, 2000, 4, 413-415.	1.4	31
47	Increased dietary levels of α-linoleic acid inhibit mammary tumor growth and metastasis. European Journal of Nutrition, 2017, 56, 509-519.	1.8	31
48	Inhibition of prostanoid synthesis protects against neuronal damage induced by focal ischemia in rat brain. Neuroscience Letters, 1998, 257, 123-126.	1.0	30
49	Monoclonal Anti-CD18 Antibody Prevents Transcellular Biosynthesis of Cysteinyl Leukotrienes In Vitro and In Vivo and Protects Against Leukotriene-Dependent Increase in Coronary Vascular Resistance and Myocardial Stiffness. Circulation, 2000, 101, 1436-1440.	1.6	30
50	Leukotriene B4Production in Human Mononuclear Phagocytes Is Modulated by Interleukin-4-Induced 15-Lipoxygenase. Journal of Pharmacology and Experimental Therapeutics, 2002, 300, 868-875.	1.3	29
51	Antagonism of thromboxane receptors by diclofenac and lumiracoxib. British Journal of Pharmacology, 2007, 152, 1185-1195.	2.7	29
52	Microrna 143–145 Deficiency Impairs Vascular Function. International Journal of Immunopathology and Pharmacology, 2012, 25, 467-474.	1.0	29
53	Cysteinyl Leukotriene-1 Receptor Activation in a Human Bronchial Epithelial Cell Line Leads to Signal Transducer and Activator of Transcription 1-Mediated Eosinophil Adhesion. Journal of Pharmacology and Experimental Therapeutics, 2008, 325, 1024-1030.	1.3	28
54	Designing Multitarget Antiâ€inflammatory Agents: Chemical Modulation of the Lumiracoxib Structure toward Dual Thromboxane Antagonists–COXâ€2 Inhibitors. ChemMedChem, 2012, 7, 1647-1660.	1.6	28

#	Article	IF	CITATIONS
55	Cyclooxygenase-1 and Prostacyclin Production by Endothelial Cells in the Presence of Mild Oxidative Stress. PLoS ONE, 2013, 8, e56683.	1.1	28
56	Synthesis of cysteinyl leukotrienes in human endothelial cells: subcellular localization and autocrine signaling through the CysLT 2 receptor. FASEB Journal, 2011, 25, 3519-3528.	0.2	27
57	Bronchodilators modulate inflammation in chronic obstructive pulmonary disease subjects. Pharmacological Research, 2012, 66, 343-348.	3.1	27
58	Critical role of COXâ€1 in prostacyclin production by human endothelial cells under modification of hydroperoxide tone. FASEB Journal, 2009, 23, 605-612.	0.2	26
59	Monitoring inflammation and airway remodeling by fluorescence molecular tomography in a chronic asthma model. Journal of Translational Medicine, 2015, 13, 336.	1.8	23
60	β2Integrin-Dependent Neutrophil Adhesion Induced by Minimally Modified Low-Density Lipoproteins Is Mainly Mediated by F2-Isoprostanes. Circulation, 2002, 106, 2434-2441.	1.6	22
61	Prostaglandin E2 possesses different potencies in inducing Vascular Endothelial Growth Factor and Interleukin-8 production in COPD human lung fibroblasts. Prostaglandins Leukotrienes and Essential Fatty Acids, 2016, 106, 11-18.	1.0	21
62	Leukotriene A4, and not leukotriene B4, is the main 5-lipoxygenase metabolite released by bovine leukocytes. FEBS Letters, 1996, 388, 94-98.	1.3	19
63	Autocrine activity of cysteinyl leukotrienes in human vascular endothelial cells: Signaling through the CysLT2 receptor. Prostaglandins and Other Lipid Mediators, 2015, 120, 115-125.	1.0	19
64	Discovery of the First in Vivo Active Inhibitors of the Soluble Epoxide Hydrolase Phosphatase Domain. Journal of Medicinal Chemistry, 2019, 62, 8443-8460.	2.9	19
65	Vasoconstriction to Polymorphonuclear Leukocytes in the Isolated, Perfused Rabbit Heart: Inhibition by Prostacyclin Mimetics. Journal of Cardiovascular Pharmacology, 1996, 27, 680-685.	0.8	19
66	Negative ion tandem mass spectrometry of leukotriene E4, and LTE4, metabolites: Identification of LTE4, in human urine. Journal of the American Society for Mass Spectrometry, 1991, 2, 314-321.	1.2	18
67	Cyclooxygenase-2-dependent generation of 8-epiprostaglandin F2α by lipopolysaccharide-activated J774 macrophages. Inflammation Research, 1999, 48, 503-508.	1.6	18
68	Proanthocyanidins from Vitis vinifera inhibit oxidative stress-induced vascular impairment in pulmonary arteries from diabetic rats. Phytomedicine, 2017, 25, 39-44.	2.3	18
69	Rapid Metabolization of Protectin D1 by β-Oxidation of Its Polar Head Chain. Journal of Medicinal Chemistry, 2019, 62, 9961-9975.	2.9	18
70	Direct airway injury results in elevated levels of sulfidopeptide leukotrienes, detectable in airway secretions. Prostaglandins, 1991, 42, 1-7.	1.2	17
71	The Potential Role of Tocopherol in Asthma and Allergies. BioDrugs, 2001, 15, 81-86.	2.2	17
72	Reduced in vivo oxidative stress following 5-methyltetrahydrofolate supplementation in patients with early-onset thrombosis and 677TT methylenetetrahydrofolate reductase genotype. British Journal of Haematology, 2005, 131, 100-108.	1.2	17

#	Article	IF	CITATIONS
73	Nitric oxide modulation of transcellular biosynthesis of cys-leukotrienes in rabbit leukocyte-perfused heart. British Journal of Pharmacology, 1997, 120, 1128-1134.	2.7	16
74	Beta2-adrenergic activity modulates vascular tone regulation in lecithin:cholesterol acyltransferase knockout mice. Vascular Pharmacology, 2015, 74, 114-121.	1.0	16
75	Montelukast Use Decreases Cardiovascular Events in Asthmatics. Frontiers in Pharmacology, 2020, 11, 611561.	1.6	14
76	A new class of nitric oxide-releasing derivatives of cetirizine; pharmacological profile in vascular and airway smooth muscle preparations. British Journal of Pharmacology, 2007, 151, 35-44.	2.7	13
77	Arachidonic Acid and Docosahexaenoic Acid Metabolites in the Airways of Adults With Cystic Fibrosis: Effect of Docosahexaenoic Acid Supplementation. Frontiers in Pharmacology, 2019, 10, 938.	1.6	13
78	[11] Quantitation of sulfidopeptide leukotrienes in biological fluids by gas chromatography-mass spectrometry. Methods in Enzymology, 1990, 187, 90-98.	0.4	12
79	An improved assay for urinary LTE4. Prostaglandins, 1994, 47, 281-292.	1.2	12
80	Nasal neutrophilia and release of myeloperoxidase induced by nasal challenge with platelet activating factor: Different degrees of responsiveness in atopic and nonatopic subjects*. Journal of Allergy and Clinical Immunology, 1996, 97, 947-954.	1.5	11
81	Pharmacological modulation of human platelet leukotriene C4-synthase. Biochemical Pharmacology, 1997, 53, 905-908.	2.0	10
82	Antiinflammatory and antioxidant effects of H2O2 generated by natural sources in Il1β-treated human endothelial cells. Prostaglandins and Other Lipid Mediators, 2015, 121, 190-198.	1.0	10
83	In vitro pharmacological evaluation of multitarget agents for thromboxane prostanoid receptor antagonism and COX-2 inhibition. Pharmacological Research, 2016, 103, 132-143.	3.1	10
84	Pharmacological Characterization of 2NTX-99 [4-Methoxy-N1-(4-trans-nitrooxycyclohexyl)-N3-(3-pyridinylmethyl)-1,3-benzenedicarboxamide], a Potential Antiatherothrombotic Agent with Antithromboxane and Nitric Oxide Donor Activity in Platelet and Vascular Preparations. Journal of Pharmacology and Experimental Therapeutics, 2006, 317,	1.3	9
85	830-837. 14,15-Dehydroleukotriene A4: a specific substrate for leukotriene C4 synthase. Biochemical Journal, 1997, 328, 225-229.	1.7	8
86	Appearance of Urinary Metabolites of LTE4in Human Subjects. Annals of the New York Academy of Sciences, 1991, 629, 105-111.	1.8	7
87	Comparative analysis of isolated human bronchi contraction and biosynthesis of cysteinyl leukotrienes using a direct 5-lipoxygenase inhibitor. Biochemical Pharmacology, 1997, 54, 437-442.	2.0	7
88	Synthesis and biological evaluation of 14,15-dehydro-LTA4 analog. Bioorganic and Medicinal Chemistry Letters, 1997, 7, 105-108.	1.0	7
89	Continuous wound infusion with chloroprocaine in a pig model of surgical lesion: drug absorption and effects on inflammatory response. Journal of Pain Research, 2017, Volume 10, 2515-2524.	0.8	7
90	CHF6001 Inhibits NF-κB Activation and Neutrophilic Recruitment in LPS-Induced Lung Inflammation in Mice. Frontiers in Pharmacology, 2019, 10, 1337.	1.6	7

#	Article	IF	CITATIONS
91	PGD2induces pulmonary hyperresponsiveness to acetylcholine in vivo in the guinea-pig. Autonomic and Autacoid Pharmacology, 1987, 7, 281-285.	0.7	6
92	IL-4 and IgE–anti-IgE modulation of 15(S)-hydroxyeicosatetraenoic acid release by mononuclear phagocytes. Journal of Allergy and Clinical Immunology, 1999, 103, 159-164.	1.5	6
93	Nonsteroidal Anti-Inflammatory Drugs: Exploiting Bivalent COXIB/ TP Antagonists for the Control of Cardiovascular Risk. Current Medicinal Chemistry, 2017, 24, 3218-3230.	1.2	6
94	Effects of Mediterranean Diet or Low-Fat Diet on Blood Fatty Acids in Patients with Coronary Heart Disease. A Randomized Intervention Study. Nutrients, 2021, 13, 2389.	1.7	5
95	Blood Fatty Acids Profile in MIS-C Children. Metabolites, 2021, 11, 721.	1.3	5
96	Actual Role of Prostaglandins in Inflammation. Drug Investigation, 1991, 3, 4-9.	0.6	4
97	Effects of nedocromil sodium on bronchospasm and HS-NCA release induced by allergen inhalation in asthmatic patients. Clinical and Experimental Allergy, 1994, 24, 281-287.	1.4	3
98	Consequences Of Transcellular Biosynthesis Of Leukotriene C4 On Organ Function. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 1996, 26, 28-36.	0.5	3
99	Transcellular Synthesis of CYS-LT: From Isolated Cells to Complex Organ System. Advances in Experimental Medicine and Biology, 1997, 433, 95-98.	0.8	3
100	Synthesis of 19-[(2-azido-5-iodo)-benzoyloxy]-LTA 4 and enzymatic conversion to the LTC 4 analogue. Bioorganic and Medicinal Chemistry Letters, 2000, 10, 665-668.	1.0	2
101	Role of sodium in intracellular calcium elevation and leukotriene B4 formation by receptor-mediated activation of human neutrophils. Biochemical Pharmacology, 2004, 67, 385-393.	2.0	2
102	Prostaglandins and gastric mucosal protection by esaprazole in rats. European Journal of Pharmacology, 1990, 187, 19-25.	1.7	1
103	The role of montelukast in cardiovascular events. Atherosclerosis, 2017, 263, e150.	0.4	1
104	Citrus flavonoids effects on human umbilical vein. Journal of Functional Foods, 2021, 86, 104731.	1.6	1
105	Transcellular biosynthesis of leukotrienes: A unique mode of cell communication. , 1999, , 113-124.		1
106	Sulfidopeptide leukotriene and acute respiratory distress syndrome. Pharmacological Research, 1990, 22, 443.	3.1	0
107	Synthesis of leukotrienes and its pharmacological control in the rabbit heart. Pharmacological Research, 1992, 25, 103-104.	3.1	0
108	Differential effects of fluticasone propionate on allergen-evoked bronchoconstriction and increased urinary leukotriene E4 excretion American Journal of Respiratory and Critical Care Medicine, 1994, 150, 287-287.	2.5	0

#	Article	IF	CITATIONS
109	Transcellular metabolism of leukotrienes and regulation of cardiac function. Pharmacological Research, 1994, 30, 353.	3.1	0
110	Leukotrienes as targets in cardiovascular disease. Clinical and Experimental Allergy Reviews, 2001, 1, 313-316.	0.3	0
111	Perspectives of Analytical Methods for Eicosanoids. , 0, , 95-102.		0
112	Estrogen Receptor-α as a Drug Target Candidate for Preventing Lung Inflammation. Endocrine Reviews, 2009, 30, 930-930.	8.9	0
113	Biomarkers Of Inflammation And Oxidative Stress In Patients With COPD And Healthy Smokers. , 2010, , .		Ο
114	The pulmonary pharmacology of [4-methoxy-N1-(4-trans-nitrooxycyclohexyl)-N3-(3-pyridinylmethyl)-1,3-benzenedicarboxamide] (2NTX-99), an anti-atherotrombotic compound with therapeutic potential in pathological conditions that target lung vasculature. Prostaglandins and Other Lipid Mediators, 2012, 98, 116-121.	1.0	0
115	In vitro pharmacological evaluation of multitarget thromboxane prostanoid receptor/COX-2 agents: A possible strategy to solve the cardiovascular issues of COXIBs. Atherosclerosis, 2016, 252, e59.	0.4	Ο
116	IL-4-Induced Lipid Mediators Class Switching in Human Normal Mononuclear Phagocytes. Advances in Experimental Medicine and Biology, 2003, 525, 15-18.	0.8	0
117	Polymorphonuclear-Endothelial Cell Interactions and the Control of Coronary Vasculature. , 1996, , 89-97.		0
118	Neutrophil-Endothelial Cells Cooperation in the Handling of Leukotrienes: Role in Coronary Inflammation. Medical Science Symposia Series, 1998, , 239-245.	0.0	0
119	Therapeutic intervention with LT synthase inhibitors and receptor antagonists in cardiovascular inflammation events. Drug News and Perspectives, 1999, 12, 91.	1.9	0
120	Montelukast and cardiovascular events: Insights from observational retrospective study. , 2019, , .		0